Silent Kidney Risk Lurking In Heart Patients

Doctors now have a rulebook that says every heart patient must get their kidneys checked, too.

Quick Take

The European Society of Cardiology (ESC) released its first-ever guideline joining heart disease and chronic kidney disease care, built around a plan called STAMP.
The rule tells doctors to test all cardiovascular patients for kidney disease using two simple measures: eGFR and albuminuria.
Patients with kidney disease, diabetes, and protein in their urine are now steered toward specific drug combinations, including newer medicines like finerenone and semaglutide.
About 100 million adults in Europe live with chronic kidney disease, and many go undiagnosed until damage is already done.

A New Rulebook Links Two Deadly Diseases

The ESC published its 2026 guideline on cardiovascular disease and chronic kidney disease on August 28, working with the European Renal Association. It’s the group’s first document built entirely around the overlap between heart and kidney trouble. The framework driving it is called STAMP: Screen, Triage, Address kidney risk, Modify heart care, and Plan health services.

Task force chairs Kevin Damman and William Herrington presented the guideline, framing it as a direct response to a problem doctors have long known about but rarely acted on systematically. Heart disease and kidney disease often travel together. Damaged kidneys raise blood pressure and strain the heart. A weak heart, in turn, starves the kidneys of blood flow. Each disease speeds up the other.

Why Every Heart Patient Now Faces a Kidney Test

The guideline calls for testing every cardiovascular patient using two measurements: estimated glomerular filtration rate (eGFR), which shows how well kidneys filter blood, and albuminuria, a urine test that catches protein leaking out too early. Doctors are told to confirm a real, ongoing problem before acting. That means running both tests twice, at least three months apart, so a temporary blip doesn’t get mistaken for lasting kidney damage.

This isn’t a brand-new idea pulled from nowhere. The American Heart Association recommended screening heart patients for kidney disease back in 2006, and the global kidney group KDIGO has long flagged heart disease as one of the top reasons to test kidney function. What’s new is the size and specificity of this joint European push, plus its attempt to standardize exact thresholds and timelines across two medical specialties that don’t always talk to each other.

The Drug Combinations Doctors Are Told to Prescribe

For most patients diagnosed with chronic kidney disease, the guideline recommends pairing an ACE inhibitor or ARB, both common blood pressure drugs, with an SGLT2 inhibitor, a newer class first developed for diabetes that also protects kidneys and hearts. For patients who also have type 2 diabetes and protein in their urine, the guideline adds two more drugs: finerenone, which blocks a hormone pathway that damages kidney tissue, and semaglutide, the GLP-1 drug already known for treating diabetes and obesity.

The reasoning is straightforward. Each drug class has shown it can slow kidney decline and cut heart risk in large trials, and stacking them targets the disease from multiple angles at once. Layering four drug classes onto one patient raises real questions about cost, side effects, and whether people will actually stick with such a complicated regimen. Guidelines can name the ideal treatment plan; convincing patients and insurers to pay for it is a separate battle.

The Scale Problem No Guideline Can Solve Alone

The ESC’s own numbers show the challenge ahead. Roughly 100 million adults in Europe live with chronic kidney disease, and the society itself admits that current nephrology and primary care staffing can’t identify and treat everyone who needs it. Screening more people only helps if there’s enough capacity downstream to act on what the tests find.

That’s why the STAMP framework’s final step, planning health services, matters as much as the testing itself. A guideline can set the standard of care. Turning it into staffed clinics, trained doctors, and covered prescriptions is a slower, messier job that falls to national health systems and insurers, not to the ESC.

For patients over 40 already managing heart disease, the message is simple: ask your doctor about a kidney function test at your next visit. Catching kidney trouble early, before symptoms even appear, gives doctors a real chance to slow the damage instead of just reacting to it once it’s severe.